The present disclosure generally relates to packaging for pharmaceuticals and, more specifically, blister packaging for pharmaceuticals.
Pharmaceutical packaging is an important aspect of delivering pharmaceuticals in an easy to dispense manner. Pharmaceutical packaging is important to the overall product in terms of protecting the pharmaceutical, as well as providing the user with an easy way to identify the correct dose.
In some embodiments, a blister package is disclosed herein. The blister package includes a body, a plurality of pockets, and a top seal. The body has a top surface and a bottom surface opposite the top surface. The plurality of pockets is formed in the body. Each of the plurality of pockets extend below the top surface of the body. Each pocket of the plurality of pockets is configured to hold a pharmaceutical. The plurality of pockets is arranged in a manner that defines at least one dose. The plurality of pockets for the at least one dose includes a first pocket in parallel with a second pocket, and a third pocket perpendicular to the first pocket and the second pocket. The top seal is configured to interface with the body. The top seal is configured to hold the pharmaceutical in each respective pocket.
So that the manner in which the above recited features of the present disclosure can be understood in detail, a more particular description of the disclosure, briefly summarized above, may be had by reference to embodiments, some of which are illustrated in the appended drawings. It is to be noted, however, that the appended drawings illustrated only typical embodiments of this disclosure and are therefore not to be considered limiting of its scope, for the disclosure may admit to other equally effective embodiments.
To facilitate understanding, identical reference numerals have been used, where possible, to designate identical elements that are common to the figures. It is contemplated that elements disclosed in one embodiment may be beneficially utilized on other embodiments without specific recitation.
Embodiments described herein generally relate to a blister package for pharmaceuticals. The blister package may be configured to include multiple doses of a pharmaceutical. For example, the blister package described herein may be configured to include multiple dosages of a COVID-19 Oral Anti-Viral pharmaceutical. Each dose may include multiple tablets associated therewith. For example, each does may include two tablets of a first pharmaceutical and one tablet of a second pharmaceutical.
As shown, plurality of pockets 104 may be arranged in a manner that defines a dose for an individual to consume. For example, although representative, blister package 100 may be configured to include a first dose 108 and a second dose 110. Each pocket 104 may be arranged to hold a specific pharmaceutical for each of first dose 108 and second dose 110. For example, as show, plurality of pockets 104 may include six pockets, pocket 1041-1046. Pockets 1041-1043 may correspond to first dose 108; pockets 1044-1046 may correspond to second dose 110.
In some embodiments, the arrangement of pockets 104 may assist the consumer in easily identifying each dose 108 and 110, as well as the pharmaceuticals corresponding to each dose 108 and 110. For example, pocket 1041 and pocket 1042 may be arranged in parallel. In some embodiments, the pharmaceutical disposed in pocket 1041 may be the same pharmaceutical disposed in pocket 1042. Pocket 1043 may be perpendicular to pocket 1041 and pocket 1042. Pocket 1043 may be a different pharmaceutical than the pharmaceutical disposed in pocket 1041 and pocket 1042. Similarly, for second dose 110, pocket 1044 and pocket 1045 may be arranged in parallel. In some embodiments, the pharmaceutical disposed in pocket 1044 may be the same pharmaceutical disposed in pocket 1045. Pocket 1046 may be perpendicular to pocket 1044 and pocket 1045. Pocket 1046 may store a different pharmaceutical than the pharmaceutical disposed in pocket 1044 and pocket 1045.
In some embodiments, blister package 100 may be thermoformed. In such techniques, each pocket 104 may be formed in body 102 during the thermoforming process.
In some embodiments, because top seal 400 interfaces with top surface 202 of blister package 100, the interfacing of top seal 400 with top surface 202 may result in a visual indication of the location of each pocket 104. For example, as shown, when top seal 400 is in place, an outline 402 of each pocket 104 may be formed. Outline 402 may help the user identify the location of each pharmaceutical in blister package 100.
In some embodiments, top seal 400 may include a visual indicator 404 that separates multiple doses in the same blister package 100. For example, as shown, visual indicator 404 may separate first dose 108 from second dose 110. In this manner, a user may be able to easily identify those pharmaceuticals associated with each respective dose.
Top seal 400 may be formed from a material that allows each pharmaceutical 106 to break through. For example, in operation, a user may apply a force to bottom surface 206 of pocket 104 to cause pharmaceutical 106 to break through top seal 400. For example, top seal 400 may be formed from one or more of aluminum, paper, plastic, and the like.
In some embodiments, top seal 400 may be configured to include information regarding the pharmaceutical contained in blister package 100. For example, as shown, top seal 400 may include information regarding the pharmaceutical, as well as visual indicators (e.g., colors) denoting each dose.
As shown, each pocket 104 may be formed substantially larger than the size of pharmaceutical 106 disposed therein. For example, pharmaceutical 106 may be disposed in pocket 104 in a manner that allows for partial movement of pharmaceutical 106 in pocket 104. For example, pocket 104 may include a depth such that there may be a space between pharmaceutical 106 and top seal 400.
It will be appreciated to those skilled in the art that the preceding examples are exemplary and not limiting. It is intended that all permutations, enhancements, equivalents, and improvements thereto are apparent to those skilled in the art upon a reading of the specification and a study of the drawings are included within the true spirit and scope of the present disclosure. It is therefore intended that the following appended claims include all such modifications, permutations, and equivalents as fall within the true spirit and scope of these teachings.
This application claims priority to U.S. Provisional Application Ser. No. 63/291,873, filed Dec. 20, 2021, which is hereby incorporated by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/081725 | 12/16/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63291873 | Dec 2021 | US |